Australia:KZA

Kazia Licenses Rights to Paxalisib in Greater China to Simcere, a Leading Chinese Pharmaceutical Company

SYDNEY, March 29, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a licensing agreement with Simcere Pharmaceutical Group Ltd (Simcere) (HKSE: 2096) to develop and commercialise...

2021-03-29 17:43 1923

Kazia Licenses Cantrixil, a Clinical-stage, First-in-class Ovarian Cancer Drug Candidate, to Oasmia Pharmacetical AB

SYDNEY, March 2, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into an exclusive worldwide license agreement with Oasmia Pharmaceutical AB (STO: OASM), an innovation-focuse...

2021-03-02 07:00 3042

Kazia to Collaborate with Pacific Pediatric Neuro-Oncology Consortium (PNOC) for New Paxalisib Combination Study in DIPG

SYDNEY, Dec. 10, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has executed a Letter of Intent with the Pacific Pediatric Neuro-Oncology Consortium (PNOC) to launch a clinical trial of...

2020-12-10 12:51 5263

Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals

SYDNEY, Dec. 9, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share top-line final data from its phase I study of Cantrixil (TRX-E-002-1) in patients with persistent or recurrent ovarian cancer (NCT029...

2020-12-09 07:49 2211

Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety And Efficacy Signals In Glioblastoma

SYDNEY, Nov. 18, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share a summary of new paxalisib data presented at the Society for Neuro-Oncology (SNO) Annual Meeting, which is being held virtually from...

2020-11-18 07:39 2145

Kazia Executes Agreement To Commence GBM Agile Pivotal Study

SYDNEY, Oct. 16, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has executed a definitive agreement with the Global Coalition for Adaptive Research (GCAR) to commence Kazia's participat...

2020-10-16 07:30 11694

Kazia Enters Clinical Collaboration With Dana-farber Cancer Institute For Primary CNS Lymphoma

SYDNEY, Sept. 22, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with Dana-Farber Cancer Institute (DFCI) inthe United States, to investigate the use of...

2020-09-22 09:21 6814

US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG

SYDNEY, Aug. 24, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Kazia's paxalisib (formerl...

2020-08-24 09:14 5684

US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma

SYDNEY, Aug. 20, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kazia's paxalisib (forme...

2020-08-20 08:35 7801

US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG

SYDNEY, Aug. 7, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia's paxalis...

2020-08-07 08:30 13069

Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs

SYDNEY, June  22, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share poster presentations of interim data from the ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most com...

2020-06-22 12:39 3288

Kazia Presents Interim Paxalisib Phase II Data at ASCO Showing Positive Overall Survival Signal

SYDNEY, June 1, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share a poster presentation of interim data from the ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most comm...

2020-06-01 08:45 4147

Kazia's Paxalisib Shows Positive Overall Survival Signal in Phase II Glioblastoma Study

SYDNEY, April 7, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share positive interim data from its ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most common and most agg...

2020-04-07 20:00 3087

Kazia Initiates Preparatory Activities to Bring GDC-0084 into GBM AGILE, an International Phase II / III Study in Glioblastoma

SYDNEY, Dec. 11, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it's lead program, GDC-0084, has been selected to join GBM AGILE, an international, academic-led, multi-drug adaptive phase ...

2019-12-11 08:41 5562

Positive Interim Efficacy Data from GDC-0084 Phase II Study in Glioblastoma Released at SNO Conference

SYDNEY, Nov. 25, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share with investors interim data from its ongoing phase II study of GDC-0084 in glioblastoma, the most common and most aggressive form of...

2019-11-25 07:00 1434

Kazia Raises A$4.0 Million to Progress R&D Programs

SYDNEY, Oct. 28, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce the completion of a placement of ten million new fully paid ordinary shares in the Company (New Shares) to institutional, profess...

2019-10-28 10:16 6305

Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer

SYDNEY, Sept. 13, 2019 /PRNewswire/ -- Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) is pleased to announce that it has been named as a winner in the 2019 ANZLF Trans-Tasman Innovation & Growth Awards. The Awards celebrate the innovation, growth and ...

2019-09-13 20:00 6598

St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway

SYDNEY, Sept. 12, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that St Jude Children's Research Hospital has successfully completed the first stage of its ongoing phase I study of Kazia's in...

2019-09-12 21:10 6902

Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer Center

SYDNEY, July 22, 2019 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that Memorial Sloan Kettering Cancer Center (MSK) inNew York, NY will investigate the potential use of Kazia's investigational ne...

2019-07-22 09:08 2468

Kazia calls for greater awareness of the deadliest brain cancer in the US

SYDNEY, July 17, 2019 /PRNewswire/ -- This Glioblastoma Awareness Day, Australian oncology-focused biotech company, Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA), calls for greater awareness of the most lethal brain cancer in the US. Glioblastoma (GBM) is the most common, complex, treatment ...

2019-07-17 20:00 7288
12